Can we treat respiratory failure in Friedreich ataxia?
BACKGROUND
Neurochemical disorders associated with spinocerebellar ataxias are multiple.


OBJECTIVE
To use replacement and neuroprotective therapy in a case of severe respiratory failure in Friedreich ataxia. PATIENT AND TREATMENT: A 44-year-old man with severe Friedreich ataxia displayed arduous periodic breathing associated with minor desaturation as well as obstructive or mixed apneas associated with severe desaturation during the night. He was given oxitriptan (5-hydroxy-L-tryptophan) (1500 mg/d), thiamine hydrochloride (100 mg/d), and amantadine hydrochloride (100 mg/d). The first sleep study was conducted during the night before treatment, whereas the second was performed during the night after 9 months of treatment.


RESULTS
After treatment, striking clinical improvement of spastic dysphonia was accompanied by significant diminution in the time spent in periodic breathing and in the number of obstructive and mixed apneas during the night. Controlled studies are needed.
Botez
M I
MI
Behavioral Neurology, Neurobiology, and Neuropsychology Unit, Hotel-Dieu Hospital, Montreal, Quebec, Canada.
Mayer
P
P
Bellemare
F
F
Couture
J
J
D006916:5-Hydroxytryptophan / Q000627:therapeutic use*; D000328:Adult; D000547:Amantadine / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000627:therapeutic use*; D005621:Friedreich Ataxia / Q000150:complications*; D006801:Humans; D008297:Male; D012131:Respiratory Insufficiency / Q000188:drug therapy* / Q000209:etiology; D013831:Thiamine / Q000627:therapeutic use*
D015259:Dopamine Agents; D000547:Amantadine; D006916:5-Hydroxytryptophan; D013831:Thiamine